Table 1 Relationship between clinical characteristics and PD-L1 and PD-1 expression in intrahepatic cholangiocarcinoma

Total number

69

8 (11.6%)

35 (50.7%)

21 (30.4%)

Age, years; median (range)

60 (34–81)

63 (46–79)

63

(43–81)

60 (50–76)

Gender

 Male

40

3 (7.5%)

18 (45%)

7 (17.5%)

 Female

29

5 (17.2%)

17 (58.6%)

14 (48.3%)

HBV infection

28

 HBsAg, positive

5 (17.9%)

13 (46.4%)

8 (28.6)

 HBsAg, negative

3 (7.3%)

22 (53.7%)

13 (31.7%)

CA19-9 > 39.9U/ml

38

 CA19-9, positive

3 (7.9%)

20 (52.6%)

9 (23.7%)

 CA19-9, negative

5 (16.1%)

15 (48.4%)

13 (41.9%)

TB > 20.5umol/L

13

 TB, positive

2 (15.4%)

7 (53.8%)

2 (15.4%)

 TB, negative

6 (10.7%)

28 (50%)

19 (33.9%)

DB > 6.8umol/L

10

 DB, positive

1 (10%)

7 (70%)

3 (30%)

 DB, negative

7 (11.9%)

28 (47.5%)

18 (30.5%)

ALT > 40U/L

16

 ALT, positive

3 (18.8%)

11 (68.8%)

5 (31.3%)

 ALT, negative

5 (9.4%)

24 (45.3%)

16 (30.2%)

AST > 40U/L

18

 AST, positive

3 (16.7%)

11 (61.1%)

5 (27.8%)

 AST, negative

5 (9.8%)

24 (47.1%)

16 (31.4%)

γ-GT > 35U/L

48

 γ-GT, positive

5 (10.4%)

28 (58.3%)

15 (31.3%)

 γ-GT, negative

3 (14.3%)

7 (33.3%)

6 (28.6%)